Retroperitoneal fibrosis associated with atenolol.
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects*; D001262:Atenolol / Q000009:adverse effects; D006801:Humans; D012185:Retroperitoneal Fibrosis / Q000139:chemically induced*; D013329:Structure-Activity Relationship
D000319:Adrenergic beta-Antagonists; D001262:Atenolol